NephroGenex (NRX) Misses Q4 EPS by 2c

NephroGenex (NASDAQ: NRX) reported Q4 EPS of ($0.60), $0.02 worse than the analyst estimate of ($0.58).

Cash, cash equivalents and short-term investments as of December 31, 2014 were approximately $28.7 million as compared to approximately $2.1 million as of December 31, 2013. The increase was driven primarily by the Company’s initial public offering completed in February 2014. With the addition of clinical sites in the Phase 3 PIONEER program, we expect to have sufficient cash on hand until early 2016.

For earnings history and earnings-related data on NephroGenex (NRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c